Illinois Municipal Retirement Fund Grows Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Illinois Municipal Retirement Fund lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 113,543 shares of the medical equipment provider’s stock after buying an additional 7,344 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.06% of Zimmer Biomet worth $11,184,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. grew its position in Zimmer Biomet by 0.5% in the 3rd quarter. Eubel Brady & Suttman Asset Management Inc. now owns 292,749 shares of the medical equipment provider’s stock valued at $28,836,000 after acquiring an additional 1,584 shares in the last quarter. Cibc World Market Inc. grew its holdings in shares of Zimmer Biomet by 10.4% in the third quarter. Cibc World Market Inc. now owns 19,905 shares of the medical equipment provider’s stock valued at $1,961,000 after purchasing an additional 1,868 shares in the last quarter. Wealthfront Advisers LLC increased its stake in Zimmer Biomet by 90.1% during the 3rd quarter. Wealthfront Advisers LLC now owns 9,270 shares of the medical equipment provider’s stock worth $913,000 after buying an additional 4,393 shares during the period. Key Financial Inc lifted its holdings in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Zimmer Biomet by 64.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,234 shares of the medical equipment provider’s stock valued at $121,000 after buying an additional 482 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZBH. Barclays reduced their price objective on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research note on Thursday. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price target for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Sanford C. Bernstein boosted their price objective on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Stifel Nicolaus set a $110.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 5th. Finally, Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $106.20.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback — ZBH topped estimates on revenue and EPS, and the company announced a new buyback that pushed the stock higher after results. Positive near-term cash-return and sales momentum were highlighted. Article Title
• Positive Sentiment: Buy-side upgrade — BTIG Research issued a “Buy” on ZBH, supporting upside sentiment among some investors. Article Title
• Positive Sentiment: Index inclusion/lift — Coverage noted ZBH’s results helped lift the Russell 1000 Healthcare index, signaling industry-level recognition of the quarter. Article Title
• Neutral Sentiment: Analyst price-target moves — Citigroup and Wells Fargo raised ZBH price targets to $98 while keeping neutral/equal-weight ratings, which signals modest upside but not a broad bullish repositioning. Article Title
• Neutral Sentiment: Hold reaffirmation — Needham reaffirmed a “Hold” on ZBH, reflecting mixed analyst conviction despite the beat. Article Title
• Neutral Sentiment: Sector context — A MarketBeat piece comparing healthcare earnings highlights peers (e.g., AstraZeneca) outperforming in profit growth, which provides cross-checks for relative performance but is not company-specific. Article Title
• Negative Sentiment: Guidance caution from salesforce changes — Deep-dive coverage flagged a U.S. salesforce overhaul that prompted management to strike a measured tone on FY26 guidance, introducing execution risk that likely weighs on the stock today. Article Title
• Negative Sentiment: Measured tone on guidance in the earnings call — Transcripts and coverage emphasize that while Q4 beat, management set cautious FY26 commentary and guidance range, which may limit investor upside until execution is clearer. Article Title

Zimmer Biomet Price Performance

ZBH stock opened at $95.14 on Friday. The stock has a market cap of $18.85 billion, a price-to-earnings ratio of 26.87, a PEG ratio of 2.71 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a quick ratio of 1.39, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The business has a 50 day moving average price of $90.05 and a 200 day moving average price of $95.64.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter last year, the company earned $2.31 earnings per share. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.